modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay

Similar documents
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,

To test the possible source of the HBV infection outside the study family, we searched the Genbank

SUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication

HCV NS3 Protease Drug Resistance

Supplementary Figure 1 Weight and body temperature of ferrets inoculated with

HCV NS3 Protease Drug Resistance

A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples

History (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11

SUPPLEMENTAL MATERIAL

Relative activity (%) SC35M

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP

Deep-Sequencing of HIV-1

Sample Metrics. Allele Frequency (%) Read Depth Ploidy. Gene CDS Effect Protein Effect. LN Metastasis Tumor Purity Computational Pathology 80% 60%

Supplementary Figure 1

Resistance to Integrase Strand Transfer Inhibitors

Resistance Workshop. 3rd European HIV Drug

Vertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients

HSV DNA replication. Herpesvirus Latency. Latency and Chemotherapy. Human Herpesviruses - subtypes. Acyclovir (acycloguanosine) {Zovirax}

CPTR title slide. A Standardized System for Grading Mutations in Mycobacterium tuberculosis for Association with Drug Resistance

SUPPLEMENTARY INFORMATION

LAL: significato clinico e biologico delle mutazioni di Bcr-Abl

Genotyping and Drug Resistance in Clinical Practice. Case Studies

Resistance of Human Cytomegalovirus to Antiviral Drugs

screening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib

Evaluation and Management of Virologic Failure

What do we need to know about RAVs clinically?

Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each

Resistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña

Hepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña

Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V

Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question

When the drugs don t work- a case of HSV encephalitis.

Resistance Characteristics of Integrase Inhibitors

Tomoyuki Shiota, Ichiro Kurane, Shigeru Morikawa, and Masayuki Saijo*

Study Design - GT 1 Retreatment

Antiviral Chemotherapy

Susanne Schnittger. Workflow of molecular investigations in JAK2-negative MPNs - the Munich experience

CREUTZFELDT-JAKOB DISEASE (CJD), CLASSIC

Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.

It has been estimated that 90% of individuals

MINIREVIEW. Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management. Jocelyne Piret and Guy Boivin*

Genetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri

Supplementary information

Case. 63 year old woman now with:

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za

LE IPERCHILOMICRONEMIE FAMILIARI

172R 172K TAM-2/172R TAM-2/172K. AZT concentration [nm] AZT concentration [nm] MgCl 2 2.5K 2.5K 5K 2.5K 5K 2.5K K 5K 2.5K 5K 2.5K 50 2.

Supplementary Figure 1 Schematic overview of the mutant virus libraries and their

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question

Introduction to the Impact of Resistance in Hepatitis C

Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy

Hepatitis C Resistance Associated Variants (RAVs)

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017

David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado

Steps in viral replication (I)

Genetic Predictors of Radiosensitivity.

Journal of Microbes and Infection,June 2007,Vol 2,No. 2. (HBsAg)2 , (PCR) 1762/ 1764

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM

The chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:

CL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3

Mutations to Integrase Inhibitors in real life

Personalized Healthcare Update

Management of NRTI Resistance

Dedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology

Supplementary Document

Monitoring for Drug Resistance by Genotyping. Urvi M Parikh, PhD MTN Virology Core Lab

Susceptibility of Herpes Simplex Virus Isolated from Genital Herpes Lesions to ASP2151, A

Received 1 July 2004/Returned for modification 23 August 2004/Accepted 6 October 2004

Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene

Antiviral Agents I. Tutorial 6

NEXT GENERATION SEQUENCING OPENS NEW VIEWS ON VIRUS EVOLUTION AND EPIDEMIOLOGY. 16th International WAVLD symposium, 10th OIE Seminar

Animal hosts Natural host Laboratory animals Rabbits Mice Rats Hamsters Newborn or suckling rodents Animal models for viral pathogenesis 4 Growth of v

The E138A substitution in HIV-1 reverse transcriptase decreases in vitro. susceptibility to emtricitabine as indicated by competitive fitness assays

Mapping by recurrence and modelling the mutation rate

NNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER

10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado

Structure of viruses

Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir

LIPOPROTEINE ATEROGENE E ANTI-ATEROGENE ATEROGENE

MID 40. Diagnosis of Viral Infections. Antiviral Therapy. Herpes Zoster. Challenges to the Development of Effective Antiviral Agents

Diagnostic Methods of HBV and HDV infections

CHAPTER 8 ONCOGENIC MARKER DETECTION FROM P53 MUTANT AMINO-ACID SUBSTITUTIONS

Fabry Disease X-linked genetic, multi-organ disorder. Fabry disease screening program in Hypertrophic p Cardiomyopathy: preliminary results.

Short communication Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes

RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients

- They come in all sizes. -- General Structure is similar.

Antiviral Therapy 2011; 16: (doi: /IMP1851)

Recurrent Antiviral-Resistant Genital Herpes in an Immunocompetent Patient

Immune pressure analysis of protease and reverse transcriptase genes of primary HIV-1 subtype C isolates from South Africa

"The End of Innocence" Revisited: Resistance of Herpesviruses to Antiviral Drugs

Emerging CMV Resistance Profile for CMX001

Received 7 March 2007/Accepted 10 May 2007

Nucleotide polymorphisms of pfcrt gene in Thai isolates of Plasmodium falciparum

WHO NIC at Research Institute of Influenza and D.I. Ivanovsky Institute of Virology INTEGRATED DATA OF INFLUENZA MORBIDITY AND DIAGNOSIS

Antiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August

HCV Resistance Associated variants: impact on chronic hepatitis C treatment

Insulin Resistance. Biol 405 Molecular Medicine

Update on Zoonotic Infections with Variant Influenza A Viruses in the USA

Transcription:

Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2. J Antimicrob Chemother 71:6-16, doi: 10.1093/jac/dkv285, PMID: 26433780 Supplementary Table 7: Resistance-associated aa changes in DNA pol gene of HSV-1 including nt changes, their location, antivirals tested as well as, methods for phenotypic testing and references. Amino acid change Nucleotide change Drug susceptibility Antivirals tested ( ratio of resistant to sensitive viral isolate or value) Domain Test methods for phenotype References Aciclovir Brivudin Penciclovir Foscarnet Cidofovir resistant sensitive (ACV) (BVDU) () () () L187stop deletion (C) nt 301 (pre NH 2-terminal, >35.5 µm >35.2 µm >32.0 µm 104.0 µm 4.4 µm modified dye uptake assay including formazan test 20211650 D368A* A1103C Exo I ACV, - 9727026 8910584 14982924 I529M A1587G delta- C ACV BVDU 10.0x 1.3x plaque reduction assay 20608173 K532T A1595C delta- C ACV 887.5 µm <660.0 µm plaque reduction assay 14670581 E545D A1635T/C delta- C ACV, BVDU - 10.0x 1.3x plaque reduction assay 20608173 Y557S* T1669A/ A1670G delta- C ACV, phosphonoacetic acid (PAA) - not given not given, mice in vivo assay 8910584 19691467 Q570R C1708A/ A1709G delta- C ACV 7.1 µm 28.2 µm yield reduction assay (enzyme linked virus inhibitory reporter assay - ELRA) 15456088 V573M* G1717A Exo ACV, 0.1 µm 6.9 µm 8.5 µm mice in vivo assay 10675401

D581A** A1742C Exo phosphonoacetic acid (PAA) - 330.0 µm 12771406 8910584 8847505 L583V C1747G Exo ACV 887.5 µm <660.0 µm 14670581 E597D* G1790T delta- C ACV, PAA - 10.0x 8.0x plaque reduction assay 3034575 A605V* C1814T delta- C ACV,, 35.0 µm 12.4 µm >660.0 µm 2.6 µm plaque reduction assay 15673740 Y608stop insertion (G) nt 1788 delta- C ACV - >25.0 µm crystal structure modeling 24055837 Q618H* G1854T/C delta- C ACV BVDU,, 0.6 µm 0.004 µm 121.4 µm 0.4 µm plaque reduction assay V621S G1861A/ T1862G delta- C ACV - 25.0 µm crystal structure modeling 24055837 A657T G1969A, >35.5 µm 9.7 µm >32.0 µm 61.1 µm 1.5 µm modified dye uptake assay including formazan test 22155911 R700G* A2098G II ACV, 2.0x not given 6.0x 9497069 9796650 R700M** G2099T II ACV, 0.06 µm 0.4x 27.4 µm 7.8 µm 10675401

L702H T2105A II 35.5 µm 194.7 µm 6.0 µm 0.3 µm plaque reduction assay 12709344 L702P T2105C II ACV, BVDU - 128.0x >257.0x plaque reduction assay 20608173 V714M* T2140A II ACV, BVDU, 0.2 µm 0.01 µm 214.5 µm 0.5 µm plaque reduction assay V715G T2144G II >443.8 µm 176.0 µm 0.04 µm plaque reduction assay 12210436 V715M G2143A II ACV, 12.7 µm 42.7 µm 0.02 µm plaque reduction assay F716L C2148A/G II ACV, 1.8x 2.9x 2.9x plaque reduction assay 20608173 A719T G2155A II ACV, 5.9x 2.2x 1.9x plaque reduction assay A719V C2156T II, >35.5 µm >35.2 µm 32.0 µm 120.1 µm 1.9 µm plaque reduction assay including formazan test, dye uptake assay, DNA reduction assay 22155911 18336925 23026414 S724N G2171A II, BVDU 0.4 µm 9.6 µm >422.4 µm plaque reduction assay including formazan test, yield reduction assay (ELRA) DNA reduction assay 15040541 24747042 23026414 S725G A2173G II - >660.0 µm plaque reduction assay 12367650

F733C T2198G II ACV >10.0 µm 107.3 µm plaque reduction assay 24075863 E771Q G2311C ACV >443.8 µm <660.0 µm plaque reduction assay 14670581 L774F* C2320T ACV, - 3.7x 3.2x DNA reduction assay, denaturing gradient gel electrophoresis, 14694096 19420083 S775N G2324A ACV >10.0 µm 27.0 µm plaque reduction assay 24075863 L778M C2332A - 5.5x 2.0x 2.0x plaque reduction assay 8218229 D780N G2338A ACV, 6.1x 2.2x 1.2x plaque reduction assay 8218229 W781V* T2341G G2342T ACV, - 14.0x 3.0x plaque reduction assay 25673718 L782I C2344A ACV, 6.4x 2.3x 1.8x plaque reduction assay P797T* C2389A ACV, PAA - not given not given plaque reduction assay 2842788 E798K G2392A ACV,, BVDU, 177.2 µm 228.8 µm 132.4 µm 496.0 µm 3.0 µm plaque reduction assay 23315323

L802F* C2404T BVDU 0.6 µm 0.02 µm 166.0 µm 0.6 µm plaque reduction assay V813M* G2437A ACV,, - 5.0x 3.0x 4.0x plaque reduction assay 9497069 N815S** A2444G ACV, BVDU,, 16.2 µm <0.2 µm >31.6 µm 24.8 µm 1.9 µm plaque reduction assay 24747042 3034575 Y818C* A2453G ACV,,, BVDU 31.1 µm 0.2 µm 6.0 µm 2.1 µm plaque reduction assay 24047739 T821M C2462T ACV, BVDU 6.3x 0.2x 2.1x G841C* G2521T ACV,,, - 177.5 µm 20.0 µm >1320.0 µm 7.4 µm plaque reduction assay 12709344 G841S G2521A ACV PAA 29.0x 2.6x plaque reduction assay 3034575 R842S* C2524A ACV, - 150x 4x plaque reduction assay 9497069 M880T T2639C I ACV BVDU 10.0x 1.3x plaque reduction assay 20608173 S889A* T2665G I ACV, PAA - 10.0x 225.0x 8337848

F891C** T2672G I ACV,, 10.0x 2.0x 10.0x 1.7x 2173770 9497069 F891Y* T2672A I ACV, PAA - 10.0 µm plaque reduction assay 2173770 V892M* G2674A I ACV, PAA - 10.0 µm plaque reduction assay 2173770 G901V G2702T I ACV 15.0 µm not given modified dye uptake assay including formazan test 26055375 D907V A2720T ACV, 3.8x 2.3x 1.6x cell growth assay 16982796 I922N* T2765A 627.0 µm 0.74 µm plaque reduction assay 12709344 Y941H T2821C I ACV, - 9.4x 0.4x 14694096 V958L* G2872C V (thumb >27.5 µm 17.2 µm >660.0 µm 4.1 µm plaque reduction assay 15673740 R959H* G2876A V (thumb BVDU 0.3 µm 0.21 µm 230.0 µm 0.5 µm plaque reduction assay 15673740 K960R* A2879G V (thumb 0.2 µm 0.08 µm 22.9 µm 2.3 µm plaque reduction assay

V N961K** C2883G/A (thumb ACV,, 5.3x not given 0.8x 1.4x 9497069 2842788 W998L* G2993T (thumb ACV, BVDU, 0.1 µm 0.01 µm 35.0 µm 1.6 µm plaque reduction assay I1028T T3083C (thumb BVDU 0.03 µm 1.9 µm D1070N* G3208A (thumb ACV, BVDU, 61.0x 0.1x 2.7x mice in vivo assay 19691467 H1228D C3682G (thumb ACV - >25.0 µm crystal structure modeling 24055837